Precision Medicine
Cardio Diagnostics CEO Outlines India Expansion and Medicare Progress in Podcast Interview
Cardio Diagnostics Holdings CEO Dr. Meesha Dogan discusses the company's growth strategy, including expansion into India and progress with Medicare reimbursement, highlighting the importance of precision medicine in cardiovascular disease prevention.
Cardio Diagnostics CEO Outlines Growth Strategy and India Expansion Amid Medicare Progress
Cardio Diagnostics Holdings CEO Dr. Meesha Dogan discusses the company's precision medicine approach to cardiovascular disease, expansion into India through partnerships, and progress in the Medicare reimbursement process.
Cardio Diagnostics Merges Precision Medicine and AI to Tackle Global Cardiovascular Disease Burden
Cardio Diagnostics Holdings (NASDAQ: CDIO) is leveraging artificial intelligence and epigenetic biomarkers to deliver personalized cardiovascular risk assessments from a simple blood test, positioning itself at the forefront of precision medicine and preventive care.
Lantern Pharma to Report First Quarter 2026 Financial Results on May 15
Lantern Pharma announced it will release first-quarter 2026 financial results and operational updates on May 15, highlighting progress in its AI-driven precision oncology pipeline and the commercial launch of its withZeta.ai platform.
Cardio Diagnostics Targets Precision Cardiology with Multi-Omic AI Platform
Cardio Diagnostics Holdings (NASDAQ: CDIO) leverages AI to integrate epigenetic and genetic biomarkers for personalized cardiovascular risk assessments, potentially transforming disease prevention and treatment.
Earth Science Tech Leverages Vertical Integration to Target Precision Medicine Market
Earth Science Tech Inc. (ETST) is building a vertically integrated healthcare platform combining compounding pharmacy, telemedicine, and clinical services to capitalize on the growing precision medicine market.
Functional Longevity Summit Dallas 2026 Aims to Bridge Clinical Innovation with Practice Sustainability
The upcoming Functional Longevity Summit in Dallas focuses on equipping healthcare providers with practical strategies to implement precision medicine and regenerative therapies while building financially sustainable practices.
10X Health Appoints Will Sliger as CMO to Drive Brand and Marketing for Precision Health Platform
10X Health names Will Sliger as Chief Marketing Officer to build the marketing engine behind its personalized health and performance platform, signaling a strategic push to scale its brand and go-to-market operations.
Precision Oncology Shifts to Combination Strategies as Resistance Challenges Persist
Cancer treatment is increasingly moving toward multi-drug regimens that combine targeted therapies with immunotherapy and chemotherapy, with Lixte Biotechnology's first-in-class PP2A inhibitor LB-100 designed to enhance existing treatments by disrupting cancer cell repair and boosting immune activity.
Aditxt Subsidiary's Protein Analysis Platform Shows Promise in Breast Cancer Treatment Study
A study published in npj Precision Oncology found that Ignite Proteomics' protein analysis platform provided more predictive insight into metastatic breast cancer treatment outcomes than traditional methods, potentially improving treatment selection.
Lantern Pharma Strengthens Board with Appointment of Dr. Lee T. Schalop to Advance AI-Driven Oncology Research
Lantern Pharma enhances its AI-driven precision oncology efforts by appointing Dr. Lee T. Schalop, a seasoned biotech leader, to its Board of Directors.
Creative Biolabs Advances Precision Medicine with Dual 3D Organoid and Tissue Slice Models
Creative Biolabs is enhancing precision medicine research by integrating 3D organoid and precision-cut tissue slice models, offering a more accurate and efficient approach to drug testing and disease modeling.
Calidi Biotherapeutics Inc. Showcases Breakthrough in Cancer Treatment with Genetic Medicine Platform
Calidi Biotherapeutics Inc. (NYSE American: CLDI) is pioneering a precision genetic medicine platform aimed at revolutionizing cancer treatment by targeting both primary and metastatic tumors with engineered viruses.
Precision Genetic Medicine Platform Offers New Hope in Cancer Treatment
Calidi Biotherapeutics Inc. is pioneering a novel approach to cancer treatment with its precision genetic medicine platform, targeting both primary tumors and metastatic sites, potentially transforming cancer care and addressing other unmet medical needs.
Lantern Pharma Advances Precision Oncology with AI-Driven Platform
Lantern Pharma Inc. leverages its AI-driven RADR(R) platform to accelerate the development of precision cancer therapies, with three lead drug candidates in clinical trials and multiple FDA designations enhancing its regulatory pathways.
Silexion's Cancer Drug Shows Promise in Precision Oncology Market
Silexion Therapeutics demonstrates significant progress in KRAS-targeted cancer treatment with their RNAi therapeutic SIL-204, positioning the company as a notable player in the rapidly consolidating precision oncology market valued in billions.